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ABSTRACT
Cancer accounts for millions of deaths every year and, due to the increase and aging of the world population, the number of new diagnosed
cases is continuously rising. Although many progresses in early diagnosis and innovative therapeutic protocols have been already set in
clinical practice, still a lot of critical aspects need to be addressed in order to efficiently treat cancer and to reduce several drawbacks caused
by conventional therapies. Nanomedicine has emerged as a very promising approach to support both early diagnosis and effective therapy of
tumors, and a plethora of different inorganic and organic multifunctional nanomaterials have been ad hoc designed to meet the constant
demand for new solutions in cancer treatment. Given their unique features and extreme versatility, nanocarriers represent an innovative and
easily adaptable tool both for imaging and targeted therapy purposes, in order to improve the specific delivery of drugs administered to
cancer patients. The current review reports an in-depth analysis of the most recent research studies aiming at developing both inorganic and
organic materials for nanomedical applications in cancer diagnosis and therapy. A detailed overview of different approaches currently under-
going clinical trials or already approved in clinical practice is provided.
VC 2019 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://
creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/1.5079943
I. INTRODUCTION
Cancer is one of the main causes of death worldwide and, accord-
ing to the World Health Organization, the number of cancer-related
deaths is going to increase up to approximately 13.2 million people a
year by 2030.1 Currently, cancer treatments rely on chemotherapy,
radiotherapy, and surgery. Unfortunately, these approaches are not
specific, since they can attack both tumor and healthy tissues, causing
adverse side effects to already debilitated patients (e.g., nausea, hair
loss, weakness, and immuno-depression).
Aggressive tumors proliferate by creating new vessels in the sur-
rounding tissues through a process termed angiogenesis. This vascula-
ture shows several abnormalities in the number of endothelial cells
and tridimensional structure, and the gaps between neighboring cells
are larger than in physiological conditions, resulting in enhanced per-
meability.2,3 Moreover, tumor tissues lack an efficient lymphatic drain-
age system. All these phenomena are at the origin of the “enhanced
permeability and retention” (EPR) effect, thanks to which some drugs
can accumulate more easily around tumor tissues with respect to
healthy ones.4 However, due to the augmented pressure at the core of
the tumor mass, common drugs penetrate with many difficulties and
are mostly retained at the periphery.2,5,6
For these reasons, there is an increasing and urgent need for
designing new tools capable of improving diagnosis and reducing
the severe reactions correlated with conventional therapies.
Recently, researchers are putting a lot of effort in creating drugs
that univocally target cancer cells and are highly bioavailable, in
order to decrease the administration doses and to prevent unde-
sired cytotoxicity and drug resistance.7 In the last two decades, a
branch of nanotechnology, namely nanomedicine, emerged as an
innovative way to exploit nanomaterials for human health, includ-
ing cancer treatment.8 Nanomedicine allows performing early
diagnosis, curing with minimal side effects, and evaluating the effi-
cacy of the treatments in a non-invasive way.
Nanoparticles are colloidal systems very small in size (from 1 up
to 1000nm), with a high surface-to-volume ratio, and morphology
and properties dependent on the components and on the preparation
protocols. They can be used as therapeutic agents (magnetic nanopar-
ticles generating hyperthermia, for instance), as drug carriers, or as
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contrast agents for imaging purposes. To be exploited in biomedical
applications, nanomaterials must be biocompatible, well characterized,
and stable in vivo. Nanoparticles can be easily engineered to enhance
their selectivity and efficacy towards tumor cells,9–13 and present sev-
eral advantages compared to traditional plain chemotherapeutic
agents: they can (i) encapsulate hydrophobic molecules, increasing
their solubility/biocompatibility and their retention time in tumoral
leaky vasculature;14–16 (ii) be conjugated with targeting ligands for
diagnostic and therapeutic purposes, improving intracellular penetra-
tion and enhancing specificity towards a selected target;17–21 and (iii)
release the drug in a stable and controlled manner.7,8,14,22 Nowadays,
several kinds of nanomaterials are under investigation for clinical pur-
poses, ranging from inorganic to organic nanocarriers, and many of
them have already been accepted or are under evaluation.
In this review, we will provide an overview of the main nanopar-
ticles that are currently tested for potential exploitation in nanomedi-
cine; applications to biological models and their current status in the
clinical context will be also described, highlighting their impact as can-
cer nanotheranostic agents.
II. NANOPARTICLES FOR NANOMEDICAL
APPLICATIONS
Usually, nano-biomaterials are synthesized from inorganic metals
or polymers and lipids; therefore, they can be generally classified as
inorganic or organic (Fig. 1).
A. Inorganic nanoparticles
This class of nanoparticles is composed of inorganic compounds,
like metal oxides or pure metals; some relevant examples are described
in the following.
Nanoshells are spherical particles composed of a dielectric core
(silica, in general) surrounded by a thin layer of metal. This structure
makes them strongly resonate with light at specific wavelengths, and
the resonance can be tuned in a large spectrum of wavelength by
manipulating the shell thickness and the nanoparticle size.23
Nanoshells can either absorb or scatter light; absorbing nanoshells are
mainly used to generate hyperthermia, whereas scattering ones are
used as contrast agents.23,24
Silica nanoparticles have an easily tunable mesoporous structure
and a high surface/volume ratio that ensure a high loading capacity
and a homogeneous distribution of drugs or imaging agents. The solid
framework composed of Si-O bonds is extremely resistant to degrada-
tion or external stresses. Moreover, they have lower toxicity and higher
biocompatibility compared to other metal oxides.25
Gold nanoparticles have peculiar optical and electrical properties,
low toxicity, and potential biodegradability.19,26,27 Moreover, gold
chemistry is relatively easy, and the synthesis can be performed by fol-
lowing simple procedures, with good yields in terms of quantity and
monodispersity. Gold nanoparticles have been investigated as a deliv-
ery system for therapeutic agents,28 in photodynamic therapy for the
treatment of cancer,29 or in diagnostics to detect biomarkers for differ-
ent kinds of diseases.30
Quantum dots (QDs) are a class of small nanoparticles (2–50 nm
in diameter) consisting of a semiconducting material, with specific
electronic and optical properties, due to their high surface-to-volume
ratio. The final size plays an important role in these properties:21 for
this reason, QDs can be synthesized with a core-shell structure, in
order to block the size of the internal core to the desired radius.
Moreover, if the shell is made of a different semiconductor with a
higher band gap, QDs properties can be tuned.31 QDs have intense
fluorescence, resistance to photobleaching, and high sensitivity for
detection; thus, they are often exploited for imaging purposes.
However, they can also be used as drug carriers in theranostic
applications.32
Iron oxide nanoparticles can mainly have superparamagnetic or
ferromagnetic properties, even though superparamagnetic ones are
preferred in nanomedicine.33 In these systems, the stimulation with a
magnetic field will produce the alignment of magnetic domains with
the applied field. When removed, the magnetisation of superparamag-
netic particles reverts to zero, and heat is released because of relaxation
processes (Brownian and/or Neel relaxations);34 conversely, in ferro-
magnetic systems, the magnetisation does not spontaneously revert to
FIG. 1. Main types of inorganic and
organic nanoparticles. Nanomedicine
comprises many kinds of nanovectors that
can be used individually or in tandem to
give the best medical performance (i.e.,
theranostic).
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zero, but a specific magnetic field (coercivity field) is needed. Heat gen-
eration is used for tumor thermal ablation through hyperthermia.
NanothermV
R
, a formulation of iron oxide nanoparticles of around
15 nm coated with aminosilane, has obtained approval for the treat-
ment of glioblastoma.35
Nanoparticles of cerium oxide (nanoceria) are also under investi-
gation for the treatment of tumors, by combining their antioxidant
properties to an efficient entrapment of chemotherapeutic agents in
their porous structure.36–38
B. Organic nanoparticles
Liposomes are made of phospholipids, lipids, and cholesterol.
Due to their amphiphilic nature, phospholipids spontaneously self-
assemble in water, forming spherical structures in which the hydro-
philic “head” faces towards the solvent, and the hydrophobic “tails”
form the lipid bilayer. Liposomes can have one or more lipid bilayers,
but they all enclose an aqueous core, mimicking the morphology of
cell membranes, and they can encapsulate both hydrophilic and
hydrophobic drugs.39 An outer layer of poly(ethylene glycol) (PEG) is
often necessary to enhance their stealth stability. PEG is known to pro-
vide steric stabilization, extended blood circulation, and reduced
uptake from the mononuclear phagocyte system.40 DoxilV
R
, MyocetV
R
or DaunoXomeV
R
are liposomal formulations already approved by the
Food and Drug Administration (FDA) for chemotherapy.41–43
Polymersomes are morphological analogous of conventional lip-
osomes, but they are composed of synthetic amphiphilic block copoly-
mers. An amphiphilic block copolymer consists of two or more blocks
of different polymers linked together by covalent bonds; one of the
blocks is a hydrophilic polymer, usually PEG, and the other one can
be any biocompatible polymer, such as poly(lactic acid),44 poly(lactic-
co-glycolic acid),45,46 polystyrene, or polycaprolactone.47 Block copoly-
mers can be designed to have specific properties in order to obtain
nanoparticles with the desired features.48 Polymersomes possess
higher stability, higher mechanical resistance, and reduced permeabil-
ity compared to liposomes.49,50
Micelles are spherical aggregates made of amphiphilic macromo-
lecules where the hydrophilic part is facing the solvent, while the
hydrophobic tails are confined in the core. Contrary to liposomes,
micelles encapsulate hydrophobic drugs in the hydrophobic core,
whereas hydrophilic drugs can be adsorbed or chemically attached to
the outer shell, usually made of PEG or poly(vinyl alcohol). The
hydrophilic shell increases the solubility and the stability of the nano-
particles in aqueous environments.51 The critical micelle concentration
of amphiphilic polymers is usually very low, therefore dilution in vivo
is not an issue for the stability of the aggregates.52
Polymer nanoparticles are either solid spheres or nanocapsules
composed by biocompatible and biodegradable polymers such as pol-
y(lactide), poly(lactide-co-glycolide), and poly (e-caprolactone), or
natural polymers like chitosan, alginate, gelatin, and albumin.53
Chitosan nanoparticles are known to form electrostatic complexes
with DNA, being thus very promising for non-viral gene therapy.54,55
Nanogels are polymeric nanoparticles where the polymers cross-link
in a porous network that ensures high drug entrapment efficiency.56
The cross-linking can be obtained through a chemical reaction with
the formation of covalent bonds, or through non-covalent interactions
(physical cross-linking). In the latter case, stability in vivo must be
carefully evaluated before final application.
Dendrimers are a class of polymers with a peculiar structure
characterized by a central core—an atom or group of atoms—and
multiple branches that end with several terminal functional
groups.57,58 The branches extend symmetrically and radially from the
core forming an overall globular shape. The advantage of dendrimers
is that their architecture can be controlled with high precision, giving
rise to well-defined and monodisperse objects. Moreover, their synthe-
sis is extremely versatile, and either natural or synthetic polymers can
be used as starting materials. Hydrophilic or hydrophobic drugs can
be incorporated in the core of the dendrimers, depending on the
nature of the monomers composing the macromolecule.
Solid lipid nanoparticles (SLNs) are made of lipids that are solids
at body temperature (fatty acids, steroids, waxes, monoglycerides,
diglycerides, or triglycerides). A small percentage of surfactants or
polymeric stabilizers in the aqueous solution are needed during the
preparation because of the high hydrophobicity of lipids. The kind of
lipids and surfactants used in the formulation will affect the physico-
chemical properties of the particles.59 PEGylated lipids are often
included in the formulation to impart steric stability and to allow for
functionalization. Hydrophobic drugs are encapsulated during the fab-
rication, whereas hydrophilic drugs need to be either chemically
attached to the components or dissolved in the hydrophilic PEG
shell.60 Compared to liposomes, lipid nanoparticles ensure a higher
drug stability and prolonged release because of their crystalline struc-
ture. Moreover, with respect to other organic nanoparticles, they do
not need organic solvents during their fabrication, making them safer
to use. However, the high crystallinity of solid lipid nanoparticles can
cause low drug loading efficiency and/or very slow drug release pro-
files. For this reason, nanostructured lipid carriers (NLCs), that include
one or more lipids liquid at room temperature (like oleic acid, for
example), are often preferred.61 Depending on the amount of liquid
lipid, its insertion will give rise to amorphous or partially crystalline
solid matrices, increased drug release rates, and facilitated drug encap-
sulation during the preparation step.62
III. FUNCTIONALIZATION, TARGETING AND
TRIGGERED RELEASE
A current challenge in nanomedicine is the synthesis of nanopar-
ticles that are selective for a specific target. This accomplishment
would reduce the side effects of the treatment and, at the same time,
would increase its efficacy. The concept of site-specific drugs was sug-
gested by the Nobel laureate Paul Ehrlich, who developed the concept
of “magic bullet” referring to drugs able to kill specific microbes with-
out harming the rest of the body.63 Since then, this view has been
extended to other areas of medicine.
Because of their size, nanoparticles tend to accumulate more in
tumor tissues with respect to normal ones64 due to the enhanced per-
meability and retention (EPR) effect. Passive targeting relies on the
fact that tumors have a leaky vasculature, different pH, and different
local temperature, and are devoid of an efficient lymphatic drainage
system65 [Fig. 2(a)]. For example, lipid-based nanovectors can reach
tumor sites regardless of their surface, and can easily enter lymphatic
circulation.66 Passive targeting, however, suffers from several limita-
tions, such as a difficult control of the process, which may induce
multi-drug resistance (MDR), a poor drug diffusion, and aspecific
accumulation in liver and spleen.67 Targeted drug delivery has solved
some of these drawbacks,68 allowing to specifically reach tumor cells,
APL Bioengineering REVIEW scitation.org/journal/apb
APL Bioeng. 3, 011502 (2019); doi: 10.1063/1.5079943 3, 011502-3
VC Author(s) 2019
accumulate the vectors locally into the tumor microenvironment, and
efficiently release the drug at the desired site, without perturbing
healthy tissues.69 This can be achieved through two different
approaches: (i) active targeting [Fig. 2(b)] and (ii) triggered release
[Fig. 2(c)].70
Active targeting aims at “programming” the nanocarriers to tar-
get specific cells after extravasation. It relies on the molecular recogni-
tion (ligand-receptor or antigen-antibody interactions) of the diseased
cells through specific receptors that are overexpressed on them, but
that are instead normally or minimally expressed on healthy cells.71,72
The ligand must have a high affinity for its receptor, and the interac-
tion must be able to trigger receptor-mediated endocytosis, after which
the intracellular release can be favored by acidic pH or enzymes.73,74 If
the affinity between the ligand and receptor is too strong, however, the
penetration of the carrier might be hindered.75
Nanocarriers for active targeting need to be functionalized with
ligands that bind specific receptors on the cell membrane.76 The strate-
gies for the functionalization are different and depend on the nature of
the materials involved. A ligand can be either adsorbed onto the parti-
cle surface (biotin-streptavidin interactions, for instance) or covalently
bound to one of the components of the nanoparticles, normally poly(-
ethylene glycol). In the second case, the conjugation can occur before
or after the preparation of the nanoparticles: the size of the ligand is
crucial in the choice of one of these two methods. Large ligands are
usually attached after the formation of the carrier, because they could
alter the hydrophilic/lipophilic balance of the component, changing
the condition in which the self-assembly takes place.77 For small
ligands, instead, both ways can be exploited. The second approach,
however, has some drawbacks: purification procedures, like centrifuga-
tion or filtration, may affect the stability and the features of the nano-
particles, and it is more difficult to demonstrate a successful
conjugation with conventional techniques.78–80
Different kinds of ligands can be used to target cancer cells, and
one of the simplest molecule that can be exploited at this aim is folic
acid. It belongs to the vitamin B family, and is essential for nucleotide
biosynthesis, while its receptor is overexpressed in several tumors,
especially in ovarian and endometrial cancers.81 PEG-coated poly-
meric nanoparticles coupled to folic acid have been developed.82 More
recently, poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles carrying
paclitaxel and functionalized with folic acid were able to efficiently
transport the drug in Caco-2 cells, paving the way to the delivery of
drugs with poor oral bioavailability.83 Another study demonstrated
that folate-decorated chitosan nanoparticles were able to univocally
deliver ligustrazine to cancer cells overexpressing folate receptors.84
Concerning cancer imaging, many studies have shown that superpara-
magnetic iron oxide nanoparticles conjugated to folic acid can be
exploited as contrast agents for magnetic resonance imaging
(MRI).85–87 The advantages of using small ligands are their low costs
and easy handling. The same applies for carbohydrates, like galactose,
lactose, or mannose, among others, that specifically bind to asialogly-
coprotein receptors88,89 and to C-type lectin receptors overexpressed
in cancer cell membranes.90 Solid lipid nanoparticles loaded with
doxorubicin have been mannosylated and tested for drug release abil-
ity and cytotoxicity in A549 cells.91
Another category of targeting ligands includes peptides and pro-
teins. Peptides are short chains of amino acids that can be easily syn-
thesized to have a particular sequence. They are stable for long time
and reduce undesired effects on the immune system. Moreover, being
small, they do not alter the physicochemical properties of the nanopar-
ticles.92,93 Cell penetrating peptides (CPPs) are often exploited to
increase the permeability of the nanoparticles. However, since they are
not specific for a particular receptor, they are often coupled with other
ligands. Angiopep-2 is a peptide derived from the Kunitz domain of
aprotinin that efficiently binds to low-density lipoprotein receptor-
related protein-1 (LRP1) of endothelial cells in the blood-brain barrier
(BBB). For this reason, it is often used to target cancer cells in the
brain.94 Apolipoproteins (Apos) interact with low-density lipoprotein
receptors as well, and they are used for the same purpose.95
Transferrin receptors (TfRs) are also overexpressed on solid tumors,
especially in glioblastoma multiforme cells,96 and on the epithelial cells
of the BBB,97 due to increased iron uptake required for cancer cell
proliferation.
Antibodies are a special class of proteins with a typical “Y” shape,
where the tips have a specific amino acid sequence called antigen-
binding fragment (Fab), that univocally binds an antigen. This kind of
interaction is highly specific and strong, making antibodies the most
effective ligands. Even though their high molecular weight can affect
the physicochemical properties of the nanoparticles or compromise
the protection of the PEG layer,98 just a very small amount of antibody
is needed to target a specific site.79 The production of conventional
antibodies is difficult and expensive; therefore, antibody fragments
containing the Fab region are often preferred, because they are safer
against non-specific binding and can be easily engineered.98,99 Human
serum albumin nanoparticles carrying loperamide have been
FIG. 2. Passive targeting, active targeting,
and triggered release. (a) Passive targeting
relies on extravasation of nanoparticles
through leaky tumor vasculature; (b) active
targeting exploits surface modified nano-
particles; and (c) triggered release is based
on stimuli-responsive nanoparticles.
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successfully conjugated to monoclonal antibodies that specifically bind
the transferrin receptor. The delivery was revealed to be efficient, and
the drug was transported across the blood-brain barrier.100 Recent
studies showed that immunoliposomes can accumulate in the brain
endothelium thanks to transferrin receptor targeting.101
Finally, a new class of ligands is represented by small syn-
thetic single-stranded RNA or DNA oligonucleotides (normally
composed of 20–60 nucleotides), called aptamers, that can form
specific shapes (helices or single-stranded loops). They are
extremely versatile, and can bind different kind of targets—pro-
teins, inorganic molecules, and cells—with a high selectivity. For
this reason, they are considered an equivalent of antibodies, but
their preparation is much simpler and cheaper,102,103 additionally
to not showing any sign of toxicity.104
Triggered release is intended as the localized release of drugs
induced by a stimulus that alters the structure of the nanocarrier.105
The main advantage of this type of system is that it is highly specific
and can be activated “on demand” without perturbing healthy tissues.
Triggers can be internal, such as variations in pH, redox conditions,
and ionic strength,106–108 or external, such as temperature, ultra-
sounds, magnetic fields, and ultraviolet/near-infrared (UV/NIR) radia-
tion. Nanocarriers can be designed to be responsive to these stimuli
and to achieve enhanced release of their cargo in a precise location.109
Moreover, external stimuli such as local hyperthermia and UV/NIR
light can enhance the permeability of blood vessels and favor deep
tissue penetration.110–112 Finally, ultrasounds can induce release of
contrast agents at the tumor site, while magnetic fields can locally
drive nanocarriers, thus triggering drug release through
hyperthermia.113
IV. NANOCARRIERS FOR DIAGNOSIS
One of the main difficulties related to cancer diagnosis is the low
sensitivity of conventional equipment. Tumors start to be detectable
when they are already around 1 cm3 in size, a stage at which they are
already able to spread in surrounding tissues, potentially creating met-
astatic lesions. Tissue biopsies for cancer diagnosis provide informa-
tion regarding the tumor grade and its histological features, but fail to
detect early stage lesions.
Recently, molecular imaging procedures have been improved
to detect early stage cancer and to monitor the tumor at the geno-
mic level in a noninvasive way, in order to predict its evolution,
and to find the best personalized therapeutic strategy.3,114 Many
innovative approaches exploit the unique features of nanoparticles
like their small size, the ability to travel along human vessels, and
their specificity mediated by conjugation to targeting molecules.
Nanocarriers can be designed and modified to reach both cell sur-
face proteins and intracellular molecules by means of endocytosis.
The vast majority of nanomaterials used for cancer diagnosis are
based on inorganic metals, like gold, silica, quantum dots, and iron
oxide nanoparticles.115
Nanoshells have been widely exploited as imaging agents, due to
their optical resonance properties and their scattering and absorption
features. In particular, they have been developed as contrast agents for
optical coherence tomography (OCT).116 Nanoshells have been also
modified by antibody conjugation, in order to target specific tumor
cell receptors for cancer imaging.117 Gold nanorods and nanocages
have been successfully used as contrast agents for photoacoustic
imaging in vivo,118,119 while mesoporous silica nanoparticles are cur-
rently used for optical and magnetic resonance imaging: a multifunc-
tional nanovector has been for example developed able to encapsulate
therapeutic or imaging agents and to achieve targeted delivery in can-
cer cells.120
Quantum dots represent the ideal tool for cancer imaging
because of their unique absorption and emission spectra,121 negligible
photobleaching, and stable fluorescence.122 They have been conjugated
to streptavidin-IgG to detect extra- and intracellular molecules, and
proved to be more photostable than conventional fluorophores.123 In a
recent study, PEGylated quantum dots were conjugated to the anti-
HER2 antibody and localized in specific tumor cells.124 QD toxicity
still raises some concerns and several studies are ongoing in order to
address this point. In 2012, a pilot study performed on primates dem-
onstrated no evident toxicity up to 90 days post-injection, but further
investigations are necessary to clarify the persistence of heavy metals
in the body.125
Superparamagnetic iron oxide nanoparticles (SPIONs) have been
applied for cancer diagnosis due to their intrinsic magnetism and the
possibility to be visualized by magnetic resonance imaging.126
Dextran-coated SPIONs have been used in vitro and in vivo as MRI
contrast agents.127,128 They can be targeted by applying an external
magnetic field and/or by functionalization with specific ligands.129,130
Efficient coupling to antibodies has provided localization in specific
tumor models in vivo.131,132 SPIONs encapsulated within a polyacryl-
amide matrix and functionalized with poly(ethylene glycol) have been
efficiently uptaken by tumor cells.133 Magnetic nanoparticles conju-
gated to fluorophores, chemotherapeutics or photosensitizing agents
FIG. 3. Combination of magnetic nanoparticles and fluorescent probes for targeted
imaging of cancer cells and tissues. Reprinted with permission from Chinen et al.
Chem. Rev. 115, 72 (2015). Copyright 2015 American Chemical Society.
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can also be exploited as theranostic devices to visualize cancer cells
and simultaneously kill them134,135 (Fig. 3).
V. NANOCARRIERS FOR THERAPY
A plethora of organic nanomaterials are currently under evalua-
tion or have been already accepted for cancer therapy. Liposomes are
highly biocompatible and stable, protecting cargoes from degradation.
Many chemotherapeutic agents have been loaded into liposomes and
delivered to cancer cells;136,137 moreover, liposomes have also been
proposed as carriers for gene delivery and silencing, providing
encouraging results both in vitro and in vivo.138–140 Many efforts have
been devoted to enhance the drug release efficiency, by making them
responsive to specific stimuli, like ultrasounds,141,142 light,143 and
hyperthermia144 for triggered release.
Polymersomes are widely exploited for drug encapsulation and tar-
geted delivery because of their high stability and biocompatibility.
Usually, drug release is triggered upon external condition variations, like
pH and redox potential, or by the presence of a magnetic field.145
Polymersomes made of poly(N-vinylpyrrolidone) (PVP), as a hydro-
philic component, and poly(dimethylsiloxane) (PDMS), as a hydropho-
bic part, are a common example of these kind of systems. Recently,
PVP-b-PDMS polymersomes conjugated to tumor necrosis factor alpha
(TNF-alpha) have been successfully tested for in vivo delivery.146
Poly(butadiene-ethylene oxide) polymersomes loaded with paclitaxel
have been demonstrated to be able to release this drug in a prolonged
and stable way, with no significant cellular toxicity.147 Block copolymers
can be also labeled with fluorescent molecules for in vivo studies,148 and
loaded with photosensitizers for photodynamic therapy.149 Moreover,
lipophilic anticancer drugs, amphiphilic dyes, and membrane proteins
have been enveloped in polymersome membranes.150–152
Micelles are widely used as carriers of lipophilic molecules due to
their high versatility and biocompatibility. Micelles can be efficiently
designed in order to be responsive to different external stimuli, such as
temperature153 and pH.154,155 High concentrations of drugs can be
intracellularly delivered through endocytosis. Micelles have been effec-
tively functionalized with an antibody directed against the epidermal
growth factor receptor (EGFR), a glycoprotein overexpressed in several
tumors.156 Micelles targeted to ab3 integrin, a regulator of cancer
angiogenesis, have been reported.157 In recent studies, the local release
of drugs from micellar nanoparticles has been achieved by exploiting
the sensitivity of mitochondria to high temperatures.158,159 A recent
preclinical study demonstrated that Genexol-PM, a paclitaxel-loaded
micelle approved by the FDA, was more efficient as a radiosensitizer
than plain taxol in murine models of non-small-cell lung
carcinoma.160
Polymeric nanoparticles are highly stable in the gastrointestinal
environment and allow controlled drug release.161 They can be func-
tionalized for targeted delivery, and many kinds of molecules, drugs,
and nucleic acids can be loaded. Chitosan nanoparticles demonstrated
to be effective in releasing siRNAs both in vitro and in vivo.162–164
Efficient oxaliplatin delivery was obtained using hyaluronic acid-
chitosan nanoparticles.165 Polymer nanocarriers can be also made
responsive to temperature and sensitive to pH changes.166,167
Dendrimers possess a branched structure that can be easily modi-
fied for high specific targeting. PEGylated poly(methylmetacrylate)
(PMMA) dendrimers have been exploited in B16F10 melanomas.168
Poly-L-lysine (PLL) dendrimers/doxorubicin complexes were able to
induce anti-angiogenic responses in in vivo tumor models.169
Interestingly, dendrimers have been extensively used to deliver con-
trast agents for MRI imaging in glioma cells.170
Lipid nanoparticles are ideal for encapsulating hydrophobic
drugs, while hydrophilic molecules can be linked to their surface.
Many research studies have focused on designing solid lipid nanopar-
ticles for delivery to cancer cells, but also as non-viral gene carrier sys-
tems.171 To this end, lipid-coated lipoplexes were fabricated to carry
antisense oligonucleotides to the liver endothelial cells.172 Since lipid
nanoparticles can the cross the blood-brain barrier, they are good can-
didates for brain tumor targeting.173 Etoposide encapsulated in
transferrin-conjugated nanostructured lipid carriers efficiently targeted
acute myelogenous leukemia cells,174 and induced cytotoxicity in
human gastric cancer cell lines and on tumor animal models.175 NLCs
delivering lapachone and doxorubicin were able to overcome multi-
drug resistance in breast cancer experimental models.176 Co-delivery
of paclitaxel and indocyanine green was also successful in combining
chemo- and photodynamic therapy in vitro and in vivo.177 Delivery of
an epidermal growth factor receptor (EGFR) inhibitor showed evident
cytotoxicity in human hepatocellular carcinoma cells.178 NLCs have
been also modified to obtain reduced immunogenicity and longer bio-
availability, and to enhance their pharmacokinetic profiles
in vivo.179,180 Finally, NLCs have been recently shown to be extremely
efficient tools for combining conventional chemotherapy to hyperther-
mia treatments, by loading their core with chemotherapeutics and
SPIONs (Fig. 4).181,182
VI. CANCER NANOMEDICINES: FROM BASIC
RESEARCH TO CLINICAL TRANSLATION
Nanomedical devices are continuously developed and opti-
mized in order to enhance the solubility and the bioavailability of
small molecules and drugs, and to specifically deliver active drugs
to diseased tissues. Approximately 250 nano-based drugs have
been commercialized or are under investigation in clinical trials,
and this number is constantly growing. Since the 1970s, 1 to 7
nanomedicines are FDA-approved each year.183 The submissions
for approval include: liposomes (33%), nanocrystals (23%), emul-
sions (14%), iron-polymer complexes (9%), micelles (6%), and
others (drug-protein complexes, drug-polymer complexes, and
polymeric nanoparticles, 15%).183 Nanomedicine covered about
15% of the total pharmaceutical market in 2014 and is predicted to
increase up to 22% in 2019 with an overall estimated business of
293.1 billion dollars by 2022, according to BCC Research.184
Oncology represents the largest area of nanomedicine market
(about 35%), while other sectors involve neurological diseases,
infections, and inflammatory and cardiovascular diseases.185
Several nanomedicines have been already approved by the FDA
and by the European Medicines Agency (EMA) for cancer diagno-
sis and therapy (Table I), and many of them are currently undergo-
ing clinical trial evaluation, possibly entering the market in the
next future.
Clinical translation of chemicals is subjected to many regulatory
and manufactory rules before definitive approval. The approval pro-
cess for a single new drug costs around 1 billion dollars and it might
take 10–15 years.186 In spite of their simple composition, many of the
chemical/physical properties of nanoparticles remain critical.187 In
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FIG. 4. Apoptotic effect of combined treatment with hyperthermia and temozolomide (TMZ) on U-87 MG glioblastoma cells. Flow cytometer analysis shows that solid lipid nano-
particles loaded with SPIONs and TMZ (LMNVs) induce apoptosis, inhibition of proliferation, and reduction of cell number after application of an external magnetic field [(a)
and (b)]. Confocal images of p53 and Ki-67 expression confirm the results obtained by flow cytometry [(a) and (c)]. Reproduced with permission from Tapeinos et al.,
Nanoscale 11, 72 (2019). Copyright 2019 The Royal Society of Chemistry.
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vivo performance has to be carefully evaluated before introducing a
new product in the industrial manufacturing process.
Far in 1995, doxorubicin-loaded PEGylated liposomes (Doxil)
were approved for acquired immune deficiency syndrome (AIDS)-
associated Kaposi’s sarcoma treatment.188 This formulation improved
doxorubicin tolerability in patients and reduced collateral effects.189
After that, other liposomes developed to treat infections
(AmbisomeV
R
), metastatic breast cancer (Myocet), and pancreatic duc-
tal adenocarcinoma in combination with 5-fluorouracil and leucovorin
(MM-398) were approved. New multifunctional liposomal nanopar-
ticles are currently in the clinical trial phase, such as ThermoDoxV
R
, a
formulation made of thermosensitive lipids that allows for a site-
specific release of doxorubicin in response to high temperature.190
Other non-lipid-based FDA-approved nanoformulations include
albumin-bound paclitaxel particles (AbraxaneV
R
), indicated for meta-
static breast cancer and recently for pancreatic ductal adenocarcinoma,
and an engineered protein combining interleukin-2 and diphtheria
toxins for the treatment of non-Hodgkin’s peripheral T-cell lympho-
mas (OntakV
R
). Nevertheless, other promising polymeric nanosystems
such as BIND-014, a polymer micelle incorporating docetaxel, poliglu-
mex (a paclitaxel-polyglutamic acide conjugate), and CRLX101 (a
cyclodextrin-PEG copolymer encapsulating camptothecin), are under
clinical trials.
Regarding inorganic nanoparticles, up until now, just some for-
mulations containing superparamagnetic iron oxide nanoparticles
(SPIONs) have been approved for clinical use for iron deficiency in
anemic patients (FerahemeV
R
), for the treatment of glioblastoma using
local tissue hyperthermia (NanothermTM),191 or as imaging agents
(FeridexV
R
/EndoremV
R
). Other inorganic nanoparticles such as
NBTXR3 (a radiosensitizer combined to radiotherapy after
intravenous injection or intratumoral administration, AGulX),192,193
Cornell dots (silica nanoparticles for imaging applications), and a few
gold nanoparticles are under clinical trials.186 Regarding active target-
ing, only a minor number of nanovectors is investigated in clinical
trials, for example immunoliposomes directed against EGFR and
polymeric nanoparticles for prostate cancer treatment,194,195 or
products investigated for cardiovascular diseases or immunological
tissue targeting.17 Actually, Ontak is the only active targeting
nanomedicine that has been approved by the FDA.
VII. CONCLUSIONS AND FUTURE PERSPECTIVES
Nowadays, nanomedicine represents one of the most promising
and advanced field of biomedical research, combining nanotechnology
and medicine to design agents with improved efficacy and safety for
human health. In the last decade, many kinds of nanomaterials have
been introduced in the biomedical field, in particular for cancer diag-
nosis and therapy. Ranging from inorganic to organic nanoparticles,
the materials and the formulation procedures that are available for
their fabrication are several, achieving high versatility, controllable size
and shape, possibility to be functionalized for targeted therapy and to
be loaded with several drugs and active molecules. Nevertheless, there
is still room for improvement, as some aspects like cytotoxicity, immu-
nogenicity, and low biocompatibility need to be addressed in a more
extensive manner, especially for inorganic systems and for some of
synthetic polymers.
In this review, we presented the most significant nanomaterials
currently investigated and evaluated for clinical applications, and
explored the most recent innovations in cancer diagnosis and therapy.
We also discussed how nanocarriers are able to reach human organs
by passive targeting, exploiting the EPR effect. However, due to a non-
TABLE I. FDA and EMA-approved nano-based formulations for cancer diagnosis and therapy.
Drug Material Application Indication(s) Year(s) References
Feridex/Endorem Dextran-coated SPION Diagnosis Imaging agent 1996 (2008) 196
GastroMARKTM; UmiremV
R
Silicon-coated SPION Diagnosis Imaging agent 2001 (2009) 197
OncasparV
R
/Pegaspargase PEGylated L-asparaginase Therapy Acute lymphoblastic 1994 198
Leukemia
Doxil/CaelyxTM Liposomal doxorubicin Therapy Kaposi’s sarcoma 1995 199
Ovarian cancer 2005
Multiple myeloma 2008
DaunoXome Liposomal daunorubicin Therapy Kaposi’s sarcoma 1996 200
Ontak Denileukin diftitox Therapy Cutaneous T-Cell lymphoma 1999 201
Myocet Liposomal doxorubicin citrate Therapy Metastatic breast cancer 2000 202
EligardV
R
PLGA [poly(lactic-co-glycolic acid)] Therapy Prostate cancer 2002 203
NeulastaV
R
/Pegfilgrastim PEGylated granulocyte-colony
stimulating factor
Therapy Neutropenia induced by chemotherapy 2002 204
Abraxane/ABI-007 Albumin-paclitaxel nanoparticles Therapy Breast cancer 2005 205
Non-small-cell lung carcinoma 2012
Pancreatic cancer 2013
MepactV
R
Liposomal mifamurtide Therapy Osteosarcoma 2009 206
Nanotherm Iron oxide Therapy Glioblastoma 2010 191
MarqiboV
R
Liposomal vincristine Therapy Acute lymphoblastic leukemia 2012 207
OnivydeV
R
/MM-398 Liposomal irinotecan Therapy Pancreatic cancer 2015 208
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specific accumulation in the tumor tissues, active targeting has become
the new trend in nanomedicine. By exploiting molecules overex-
pressed just on the cancer cell surface, in fact, active targeting has
reached a high level of precision and selectivity, guaranteeing the
exclusive uptake of nanoparticles in tumor cells. Future research stud-
ies will help in elucidating the molecular and the cellular mechanisms
that mark healthy from pathological cells, giving a boost to the design
of highly performant nano-delivery systems as tools for treating can-
cer. Finally, future improvements in nanomaterial characterization
procedures will meet the most relevant issues required for the eventual
approval of nano-drugs in clinical practice.
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